Found Semaglutide: The Compounded Pathway and Oral vs Injectable

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide is the compound behind much of the GLP-1 telehealth conversation, so understanding how a given program handles it matters more than the brand name attached to it. This independent review focuses on semaglutide within Found. Browse the Peptides & GLP-1 education library.

Full head-to-head: PlexusDx vs Found →

PlexusDx offers this as editorial analysis. We have no commercial relationship with Found or its parent company, and no affiliate links or compensation are involved.

This piece walks through how semaglutide is prescribed in a telehealth model, what the 503A compounded pathway means, how oral and injectable formats differ, and the biology underneath. Balanced framing, not a buying recommendation. As of April 2026.

Semaglutide within the Found program

Semaglutide is a GLP-1 receptor agonist, and in a telehealth model it reaches patients after a licensed clinician reviews intake and issues a prescription. Whether that prescription is for a branded product or a compounded preparation depends on eligibility and program structure, detailed on Found's own website.

The 503A compounded pathway

Compounded semaglutide is prepared by a state-licensed 503A compounding pharmacy against an individual prescription, rather than dispensed as an FDA-approved brand product from a retail pharmacy. That distinction matters for how the medication is sourced, formatted, and priced, and it is a legitimate route with its own regulatory framing. A 503A pharmacy compounds for a specific patient rather than mass-producing a labeled product, which is why the pathway exists alongside, not in place of, branded manufacturing. Anyone weighing a compounded program should confirm the pharmacy's licensure through the program's own materials.

Oral versus injectable semaglutide

Semaglutide exists in both injectable and oral forms, and they are not interchangeable in dosing or administration. Injectable formats are the more established route for the compound, while oral formats offer a needle-free option that some patients prefer. The right choice is a clinical decision made with a provider, and availability of each depends on the program and pharmacy. A compounded pathway and a branded pathway may not offer the same formats, so the option you want and the option you can access are not always the same thing.

Evidence behind semaglutide for weight management

The STEP program, published in The New England Journal of Medicine in 2021, is the trial evidence most tied to semaglutide for weight management. It studied the compound across defined populations and endpoints. STEP characterizes semaglutide the molecule, not any brand or telehealth program, and individual outcomes vary from one person to the next.

The genes that shape semaglutide's baseline

Semaglutide, oral or injectable, acts on a metabolic baseline your genes help set. Variants in GLP1R, the receptor semaglutide targets, and FTO, the fat-mass and obesity-associated gene, describe that terrain. These are pathway-level markers, not response predictions. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including FTO variants that map your baseline receptor and energy-balance biology before any semaglutide protocol.

PlexusDx semaglutide options

PlexusDx offers semaglutide through its Weight Management Protocols as Semaglutide Injection and Semaglutide Oral, paired with the upstream genetic context most telehealth-only programs omit. Placing the pathway insight beside the format choice is the difference, so the conversation begins with your baseline biology rather than with whichever format a program happens to stock.

No affiliation: PlexusDx is independent of Found and holds no commercial relationship with the programs discussed here.

More from the PlexusDx library: Rybelsus BMI, Rybelsus Cheap, Rybelsus For Fatty Liver, and Rybelsus vs Tirzepatide.

Disclaimer: This article is educational. PlexusDx is not affiliated with Found and compares approaches across the GLP-1 telehealth space, including its own Weight Management Protocols. The Precision Peptide Genetic Test examines how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before starting any peptide protocol.

Frequently Asked Questions

What does compounded semaglutide mean?

Compounded semaglutide is prepared by a state-licensed 503A pharmacy against an individual prescription, rather than dispensed as an FDA-approved brand product from a retail pharmacy. It is a legitimate pathway with its own regulatory framing, and it differs from branded semaglutide in how the medication is sourced and priced.

Is oral semaglutide the same as the injectable?

No. Oral and injectable semaglutide differ in dosing and administration and are not interchangeable. Injectable formats are the more established route, while oral offers a needle-free option. Which is appropriate is a clinical decision, and availability depends on the program and pharmacy involved.

What did the STEP program show about semaglutide?

The STEP trials, published in NEJM in 2021, examined semaglutide for weight management across defined populations and endpoints. The findings describe the compound itself rather than any brand or telehealth program, and individual outcomes vary depending on many personal and clinical factors.

Which genes relate to semaglutide biology?

Pathway-level variants such as, the receptor semaglutide targets, and FTO, tied to fat mass and obesity, describe the baseline the compound acts on. They do not predict response. The Precision Peptide Genetic Test reads these markers to add upstream context for your provider conversation.

Continue in the PlexusDx Education Hub. Browse Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.